https://www.selleckchem.com/pr....oducts/Etopophos.htm
6, P 0.001), and complete tumor resection (OR 1.5, P 0.003). Neoadjuvant radiation [hazard ratio (HR) 0.7, P = 0.003] and complete tumor resection (HR 0.6, P 0.001) were significantly associated with improved overall survival (OS). Performance of PBx was not associated with OS (HR 1.1, P = 0.07, and following propensity matching, 5-year OS did not differ between the two groups (56.5% PBx vs 58.4% no PBx, P = 0.247). A minority of patients with non-metastatic RPS undergo PBx. PBx does not negatively impact survival, bu
Like
Comment
Share
